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Purpose: The primary end point of this phase III trial was to compare the response rate (RR) of oxa-
liplatin (OXA) plus levo-folinic acid (l-FA) and 5-fluorouracil (5-FU) bolus with that of irinotecan
(IRI) plus l-FA and 5-FU bolus in advanced colorectal carcinoma.
Patients and methods: Patients with measurable metastatic colorectal carcinoma were randomly
allocated to receive: IRI 200 mg/m2 on day 1, l-FA 250 mg/m2 intravenously plus 5-FU 850 mg/m2
on day 2 (IRIFAFU); or OXA 100 mg/m2 on day 1, l-FA 250 mg/m2 plus 5-FU 1050 mg/m2 on day
2 [OXAFAFU high dose (hd)]. Cycles were given every 2 weeks. After a planned interim analysis,
OXA was reduced to 85 mg/m2 and 5-FU to 850 mg/m2 [OXAFAFU low dose (ld)].
Results: Two hundred and seventy-four patients (IRIFAFU, 135; OXAFAFUhd, 71; OXAFAFUld,
68) were treated. Forty-two confirmed responses were achieved with IRIFAFU, 29 with OXAFA-
FUhd and 32 with OXAFAFUld. The response rate with OXAFAFU [44%; 95% confidence interval
(CI) 35% to 52%] was significantly higher (P = 0.029) than that of IRIFAFU (31%; 95% CI 23% to
40%). Occurrence of grade >_3 neutropenia with OXAFAFUld was similar to that for IRIFAFU
(29% versus 31%), while severe diarrhoea was significantly lower (12% versus 24%). Median fail-
ure-free survival (7 versus 5.8 months; P = 0.046) and overall survival of patients (18.9 versus 15.6
months; P = 0.032) were significantly prolonged with OXAFAFU.
Conclusions: OXAFAFU was more active and less toxic than IRIFAFU, and it should be preferred
in the first-line treatment of advanced colorectal cancer patients.
Key words: 5-fluorouracil, irinotecan, metastatic colorectal carcinoma, oxaliplatin, randomized trial.
Introduction
For decades, 5-fluorouracil (5-FU) has been the only available
drug for the treatment of metastatic colorectal carcinoma. 5-
FU has usually been administered as an intravenous (i.v.)
bolus and/or infusion, concurrently with folinic acid (FA),
methotrexate (MTX) or both, in order to achieve greater
activity than 5-FU alone [1–4]. This approach has recently
been demonstrated to minimally prolong the survival of
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patients in comparison with 5-FU alone [5]. In contrast,
despite different toxicity profiles, a similar survival was seen
whichever schedule was used, i.e. weekly, biweekly or
monthly [6, 7].
During the last decade, new drugs have shown activity in
this disease. First, irinotecan (IRI) has been proven to prolong
survival and improve quality of life of 5-FU-refractory
patients [8], and to have an activity comparable to FA/5-FU in
the first-line setting [9]. These findings suggested the lack of
cross-resistance between IRI and FA/5-FU, supporting the
commencement of trials testing their combination in front-line
treatment. Saltz et al. [9] reported on IRI plus FA/5-FU bolus
given for four consecutive weeks every 6 weeks (IFL regi-
men). The response rate (RR) was significantly greater (39%
versus 21%), and progression-free survival (PFS) (median 7
versus 4.3 months) and overall survival (OS) (median 14.8
versus 12.6 months) were significantly longer with the IFL in
comparison with those obtained with the Mayo Clinic regi-
men. Douillard et al. [10] administered the AIO or LV5FU2
regimen recycled either weekly or biweekly, alone or com-
bined with IRI. RR (35% versus 22%), PFS (median 6.7 ver-
sus 4.4 months) and OS (median 17.4 versus 14.1 months)
favoured the IRI-including treatment. In the Southern Italy
Cooperative Oncology Group (SICOG) trial 9801, IRI was
given biweekly on day 1, followed by levo-FA (l-FA) and
5-FU bolus on day 2. This IRIFAFU regimen produced a sig-
nificantly greater RR (36% versus 20%) and longer PFS
(median 7.2 versus 4.8 months) in comparison with a double
modulation of 5-FU by means of MTX and l-FA [11]. How-
ever, OS for the two arms was similar (14.7 versus 14.8
months, respectively).
Oxaliplatin (OXA) has shown activity in vitro against
5-FU-resistant colon cancer cell lines [12], and it is effective
in both chemonaı¨ve and 5-FU-pretreated patients [13–15].
Interestingly, preclinical studies have shown the greatest cell
kill when OXA was followed by a short rather than prolonged
5-FU exposure [16]. However, in early clinical trials OXA
was usually combined with chronomodulated or flat infusional
5-FU [17–20]. In front-line, the FOLFOX4 regimen obtained
a significantly greater RR (51% versus 23%) and longer PFS
(median 9 versus 6.2 months) in comparison with LV5FU2.
OS was also longer (median 16.2 versus 14.7 months) [20].
Conversely, there are still few clinical data about efficacy of
OXA and FA/5-FU given as bolus. Some investigators have
explored the addition of OXA to FA/5-FU delivered daily for
5 days (i.e. Machover or Mayo Clinic regimen). Activity was
reported in 40% to 45% of patients [21, 22], but toxicity was
substantial. More recently, Hochster et al. [23] administered
OXA 85 mg/m2 on day 1 and 15, and FA 20 mg/m2 plus 5-FU
500 mg/m2 on days 1, 8 and 15, recycling every 28 days,
achieving a 63% RR and a 15.9 month median OS in 41
patients. The Nordic Group explored the addition of OXA
85 mg/m2 to a combination of FA 60 mg/m2 and 5-FU
500 mg/m2 given for two consecutive days, administered
biweekly, obtaining a 62% RR and a median OS of 16.1
months [24].
Therefore, the combination of OXA and FA/5-FU bolus
showed promising activity in metastatic patients. For these
reasons, we carried out a phase I study to find the recom-
mended doses for an OXA plus FA/5-FU bolus biweekly regi-
men (OXAFAFU). Although the maximum tolerated doses
were not reached up to 130 mg/m2 for OXA and 1050 mg/m2
for 5-FU, some concern about the occurrence of cumulative
neurotoxicity suggested OXA 100 mg/m2 was not exceeded in
further evaluation. Therefore, we set up a multicentre random-
ised phase III trial to assess the activity and toxicity of OXA-
FAFU, and to compare this new regimen with the IRIFAFU in
metastatic colorectal cancer patients [25].
Patients and methods
Patient selection
Main inclusion criteria were: histologically proven diagnosis of adenocar-
cinoma of the colon or rectum; age >_ 18 years and life expectancy >3
months; Eastern Cooperative Oncology Group performance status (PS)
<_ 2; metastatic unresectable disease; at least one bidimensionally measur-
able lesion; neutrophils count >_2000/mm3, platelet count >_ 100 000/mm3,
bilirubin <_ 1.25 upper normal limit (UNL), alanine aminotransferase and
aspartate aminotransferase <_ 5 UNL; and normal renal function (calcu-
lated creatinine clearance >_60 ml/min). Patients previously exposed to pal-
liative chemotherapy as well as those who had received adjuvant
treatment within the last 6 months were excluded. Other main exclusion
criteria were: inflammatory bowel diseases or significant diarrhoea during
the last week, previous total colectomy or ileostomy, bowel obstruction;
uncontrolled metabolic disorders or active infections; severe cardiac
arrhythmia, or acute myocardial infarction in the last 6 months; sympto-
matic cerebral metastasis; concomitant or previous malignant tumour.
This protocol was approved by the Independent Ethics Committee of the
National Tumour Institute of Naples, and written informed consent was
required from each patient.
Patients evaluation
Medical history and physical examination were taken at study entry. Bio-
chemistry profile, blood cell count with white cell count and differential,
and carcinoembryonic antigen (CEA) serum level assessment, were rou-
tinely performed. Target lesions were measured by computed tomography
(CT) or magnetic resonance imaging (MRI) scans no more than 4 weeks
before initial therapy. During treatment, white cell count with differential
was performed weekly. Biochemistry, symptoms, body weight and non-
haematological toxicity were checked before each cycle. Toxicity was
scored according to WHO criteria [26]. Neuropathy was defined according
to the Le´vi scale [27]. For the study purpose, the worst toxicity suffered
by each patient during the whole treatment was recorded.
CT or MRI scans were repeated after every four cycles, and at the end
of treatment. Response was defined according to WHO criteria [26].
Responses were reassessed 8 weeks after their first documentation, and
only confirmed responses were computed in the activity analysis. Duration
of response was calculated from initial therapy up to documented pro-
gression of disease (PD), or last follow-up. Failure-free survival (FFS)
was calculated from registration to the time of treatment discontinuation
for any reason (occurrence of progression or unacceptable toxicity,
because of patient’s refusal or when it was deemed in the patient’ best
interest by the attending physician). OS was calculated from registration
to death for any cause, or patient’s last follow-up.
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Treatment
Patients were stratified according to centre, previous adjuvant chemo-
therapy and PS, and randomly allocated to receive: IRI 200 mg/m2 i.v.
(90 min) on day 1, l-FA 250 mg/m2 i.v (2 h), 5-FU 850 mg/m2 i.v. bolus
on day 2 (IRIFAFU regimen); or OXA 100 mg/m2 i.v. (2 h) on day 1,
l-FA 250 mg/m2 i.v. (2 h), 5-FU 1 050 mg/m2 i.v. bolus on day 2 [OXA-
FAFU high dose (hd)]. In both arms, cycles were repeated every 2 weeks.
A planned interim analysis on toxicity was carried out when half of the
target population had been treated, to assess whether frequency of febrile
neutropenia exceeded 10% of patients, which was the predefined restraint
for dosage amendment. At that time the actual occurrence of febrile neu-
tropenia among patients treated with OXAFAFUhd was 13%, and there-
fore the study regimen was amended: OXA and 5-FU were reduced to
85 mg/m2 and 850 mg/m2, respectively [OXAFAFU low dose, (ld)] for the
subsequent patients.
Cytotoxic drugs in each doublet were reduced by 25% after occurrence
of grade 4 haematological toxicity, or grade 3 non-haematological tox-
icity, on previous cycle. Chemotherapy was administered until the con-
firmed achievement of a complete response (CR) (minimum of eight
cycles), or up to 12 cycles. Treatment was discontinued earlier in the case
of documented PD, unacceptable toxicity, patient’s refusal or when it was
believed in the best patient’s interest by the attending physician. After PD,
a cross-over policy, i.e. IRIFAFU in second-line after OXAFAFU in first-
line and vice versa, was advised but not mandatory.
Statistical considerations
We assumed that the OXAFAFU regimen might increase by 50% (from 5
to 7.5 months) the median FFS in comparison with the IRIFAFU regimen.
With 257 events on the whole series of patients there is an 80% power to
demonstrate this difference with a 0.05 alpha error [28]. Therefore, a
recruitment of 280 patients has been planned for the comparative analysis.
This number of patients may also give an 80% power to detect a 15%
difference in RR between the OXAFAFU and IRIFAFU [29].
The occurrence of responses and toxicities was compared using the
x2-test or Fisher’s exact test where appropriate [30], and a P value <0.05
was considered significant. Univariate and multivariate analyses were per-
formed for identifying factors associated with RR. Actuarial median [with
95% confidence interval (CI)] of FFS and OS times were obtained
using the Kaplan–Meier method [31], and compared using the log-rank
test [32].
Results
Patient characteristics
From January 2001 to June 2003, 288 patients were registered
onto this study. However, 12 (4%) patients did not meet the
inclusion criteria, and were excluded, leaving 276 patients for
randomisation. Before amendment (June 2002), 74 patients
were randomly allocated to receive IRIFAFU, and 71 patients
to receive OXAFAFUhd. Thereafter, 62 patients were
assigned to IRIFAFU, and 69 patients to OXAFAFUld.
Patients’ results were well-balanced with respect to stratifica-
tion factors and other baseline characteristics (Table 1).
Delivered treatments
Two patients (one allocated to receive IRIFAFU, and another
to receive OXAFAFUld) refused the assigned regimen.
Patients treated with IRIFAFU received a median number of
eight (range one to 16) cycles, and stayed on study for a
median of 16 weeks (range 2–44). Median number of cycles
was eight (range one to 12) for both OXAFAFUhd and OXA-
FAFUld patients. These patients received the allocated treat-
ment for a median of 18 weeks (range 2–40) and 22 weeks
(range 2–39), respectively. A slightly higher proportion of
patients treated with IRIFAFU (19%) dropped out for refusal
or toxicity compared with those treated with OXAFAFUhd
(11%) or OXAFAFUld (12%) (Table 2).
Dose intensity and OXA cumulative dosage
Among patients treated with IRIFAFU, dose intensity (DI)
slightly decreased over time: median DI over the first four
cycles (DI4) was 88 mg/m
2/week for IRI and 372 mg/m2/week
for 5-FU; corresponding values were 82 mg/m2/week and
343 mg/m2/week over eight cycles (DI8), and 76 mg/m
2/week
and 346 mg/m2/week over 12 cycles (DI12).
A similar trend was seen for OXAFAFUhd: DI4 was
41 mg/m2/week for OXA, and 426 mg/m2/week for 5-FU,
while DI8 was 37 mg/m
2/week and 374 mg/m2/week, and DI12
was 39 mg/m2/week and 354 mg/m2/week, respectively. DI
was quite similar for OXAFAFUld: DI4 was 39 mg/m
2/week
for OXA and 417 mg/m2/week for 5-FU; DI8 was
34 mg/m2/week and 344 mg/m2/week, and DI12 was
35 mg/m2/week and 327 mg/m2/week, respectively. Cumulat-
ive OXA dosage was 705 mg/m2 (range 100–1200) with
OXAFAFUhd, and 780 mg/m2 (range 82–1114) with OXA-
FAFUld.
Activity
There were 42 confirmed responses (16 CRs and 26 PRs)
among patients treated with IRIFAFU, 29 (seven CRs and 22
PRs) among patients treated with OXAFAFUhd and 32 (13
CRs and 19 PRs) among patients treated with OXAFAFUld.
CRs were usually achieved in patients with a limited spread of
disease. In detail, 12 of 16 CRs in IRIFAFU group were
achieved in patients with only one involved organ (which was
the liver in eight cases); in OXAFAFUhd group, six of seven
CRs had only one site of disease (liver in four cases), while in
OXAFAFUld group, eight of 13 CRs had a single metastatic
site (liver in five cases).
In all, OXAFAFU yielded a significantly higher RR (44%;
95% CI 35% to 52%) than IRIFAFU (31%; 95% CI 23% to
40%) (P= 0.029). The proportion of patients achieving a PR
was also greater among patients treated with OXAFAFU
(29% versus 19%; P= 0.002), while no difference was seen in
occurrence of CRs (14% versus 12%), although a non-signifi-
cant trend towards a higher achievement of CRs was observed
among patients treated with OXAFAFUld. The difference in
RR between IRIFAFU and OXAFAFUld was also significant
(P = 0.032). Moreover, the rate of disease control (response or
stabilisation) was greater with OXA (66%) than with IRI
(58%) (Table 3).
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Regardless of treatment, RR was adversely affected by sev-
eral baseline characteristics: PS >_1, presence of symptoms of
disease, loss of body weight, CEA baseline value >100 ng/ml,
no primary surgery and two or more disease sites. Including
these factors together with the type of treatment in the multi-
variate analysis, only a good PS (P= 0.000), the OXAFAFU
regimen (P= 0.011) and a low CEA baseline value (P= 0.035)
showed a significant correlation with RR.
Time to response achievement was 2.9 months (range 1.6–
9) for IRIFAFU, and 3.2 months (range 1.7–9.3) for OXA-
FAFU. Median duration of CRs was 5.2 months (range 2–19)
in the IRIFAFU group, 17.2 months (range 2.4–25.3) in the
OXAFAFUhd group and 8.5 months (range 2–16.4) in the
OXAFAFUld group. Median duration of all responses was 7.9
months (range 1.9–20.8) for patients treated with IRI, and 8.5
months (range 1.5–22.1) for patients treated with oxaliplatin
(OXAFAFUhd, 10.5 months; OXAFAFUld, 7.9 months).
Table 2. Summary of administered treatments
Treatment IRIFAFU
(n= 135)
OXAFAFUhd
(n= 71)
OXAFAFUld
(n= 68)
Total number of cycles 1022 549 572
Median cycles/patient (range) 8 (1–16) 8 (1–12) 8 (1–12)
No. of patients (%) receiving
>_4 cycles 117 (87) 63 (89) 61 (90)
>_8 cycles 77 (57) 40 (56) 46 (68)
>_12 cycles 41 (30) 18 (25) 23 (34)
No. of patients (%) off treatment
As per protocol 96 (71) 54 (76) 50 (74)
Refusal 15 (11) 6 (8) 6 (9)
Toxicity 11 (8) 2 (3) 2 (3)
Disease complication 3 (2) 5 (7) 5 (7)
Physician’s decision 10 (7) 4 (6) 5 (7)
IRIFAFU, biweekly bolus FA/5-FU + irinotecan; OXAFAFUhd, biweekly
bolus FA/5-FU + oxaliplatin, high doses; OXAFAFUld, biweekly bolus
FA/5-FU + oxaliplatin, low doses; FA, folinic acid; 5-FU, 5-fluorouracil.
Table 1. Characteristics of eligible patients according to treatment
Characteristics IRIFAFU OXAFAFUhd OXAFAFUld OXAFAFU
n % n % n % n %
Eligible patients 136 100 71 100 69 100 140 100
Males 72 53 46 65 35 51 81 58
Females 64 47 25 35 34 49 59 42
Median age, years (range) 62 (38–80) 62 (41–79) 63 (37–76) 62 (37–79)
Aged >_ 70 years 22 16 16 22 12 17 28 20
Primary
Colon 97 71 51 72 50 72 101 72
Rectum 39 29 20 28 19 28 39 28
Previous surgery 111 82 49 69 55 80 104 74
Previous adjuvant chemotherapy 34 25 19 27 15 22 34 24
ECOG PS
0 82 60 33 47 42 61 75 54
1 50 36 35 49 26 38 61 44
2 4 4 3 4 1 1 4 3
No. of metastatic sites
1 73 54 31 44 38 55 69 49
2 49 36 32 45 23 33 55 39
3+ 14 10 8 11 8 12 16 11
Liver involvement 99 73 56 79 52 75 108 77
Synchronous metastasis 82 60 43 61 46 67 89 64
Weigh loss >_ 5% during last 6 months 45 33 20 28 26 38 46 33
Symptoms of disease 50 37 31 44 28 41 59 42
CEA value >5 ng/ml 91 67 48 68 50 72 98 70
CEA value >100 ng/ml 35 26 25 35 14 20 39 28
IRIFAFU, biweekly bolus FA/5-FU + irinotecan; OXAFAFUhd, biweekly bolus FA/5-FU + oxaliplatin, high doses; OXAFAFUld, biweekly bolus FA/5-
FU + oxaliplatin, low doses; FA, folinic acid; 5-FU, 5-fluorouracil; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoem-
bryonic antigen.
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Off-study treatments
Soon after the discontinuation of front-line treatment, nine
patients with PR (three in the IRIFAFU group and six in the
OXAFAFU group) were rendered disease-free by surgical
resection of liver metastases.
At progression after first-line IRIFAFU, 77 (57%) patients
received second-line treatments. Among these, 62 patients
received OXA associated with 5-FU or capecitabine. Local
treatment of liver metastases (radiofrequency ablation or
intra-arterial chemotherapy) was performed in five patients.
Eighteen (13%) patients received a third-line treatment (oral
fluoropyrimidines). Among patients receiving OXAFAFU in
front-line, salvage treatments were delivered in 78 (56%)
patients: IRI, alone or combined with 5-FU or mitomycin C,
was administered in 52 patients. Six patients underwent local
management for liver metastases. Twenty (14%) patients
received third-line treatment with oral fluoropyrimidines.
Toxicity
At interim analysis, neutropenia was more pronounced with
OXAFAFUhd than with IRIFAFU (grade >_3, 55% versus
39%; P= 0.029), and febrile neutropenia was more frequent
(19% versus 9%; P= 0.041) After dosage amendment, despite
a greater occurrence of thrombocytopenia of any grade with
OXAFAFUld, no difference in severe haematological toxicity
was seen between this regimen and the reference treatment
(Table 4). As for non-haematological toxicity, occurrence of
diarrhoea was significantly lower among patients treated with
OXAFAFUld, and grade >_3 was less frequent (12% versus
28%; P = 0.005). The proportion of patients complaining of
severe emesis was more than halved (4% versus 10%;
P= 0.113). Hair loss was also less pronounced with OXA-
based treatment. Grade 3 neuropathy was recorded in 14% of
patients treated with OXAFAFUhd, and in 3% of patients
treated with OXAFAFUld, despite similar OXA cumulative
Table 4. Frequency of toxicity according to treatment (underlined percentages reported with OXAFAFU regimens are significantly different from those
reported with IRIFAFU regimen)
Toxicity IRIFAFU
(n= 135)
OXAFAFUhd
(n= 71)
OXAFAFUld
(n= 68)
OXAFAFU
(n= 139)
Grade Any >_ 3 Any >_ 3 Any >_3 Any >_ 3
Neutropenia 59 31 78 55 49 29 65 40
Febrile neutropenia/infections 9 7 19 13 3 3 11 7
Anaemia 33 1 35 2 35 1 35 3
Thrombocytopenia 10 1 32 4 29 3 32 4
Emesis 62 10 54 4 53 4 54 6
Diarrhoea 66 28 44 13 32 12 39 11
Stomatitis 23 3 35 6 15 4 26 4
Fatigue 5 2 6 4 7 3 6 3
Neuropathy 5 1 48 14 47 3 48 7
Cholinergic 10 2 0 0 0 0 0 0
Hair loss 49 23 23 1 9 2 16 1
Allergic 1 0 4 1 7 1 5 1
Treatment-related death – 2 – 1 – 1 - 1
IRIFAFU, biweekly bolus FA/5-FU + irinotecan; OXAFAFUhd, biweekly bolus FA/5-FU + oxaliplatin, high doses; OXAFAFUld, biweekly bolus
FA/5-FU + oxaliplatin, low doses; FA, folinic acid; 5-FU, 5-fluorouracil.
Table 3. Activity reported according to treatment
Responses IRIFAFU OXAAFUhd OXAFAFUld OXAFAFU
n % n % n % n %
Complete response 16 12 7 10 13 19 20 14
Partial response 26 19 22 31 19 28 41 29
Stable disease 36 27 15 21 15 22 30 22
Progressive disease 38 28 19 27 14 21 33 24
Not assessed 19 14 8 11 7 10 15 11
Treated patients 135 100 71 100 68 100 139 100
IRIFAFU, biweekly bolus FA/5-FU + irinotecan; OXAFAFUhd, biweekly bolus FA/5-FU + oxaliplatin, high doses; OXAFAFUld, biweekly bolus FA/5-
FU + oxaliplatin, low doses; FA, folinic acid; 5-FU, 5-fluorouracil.
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dosages. This finding might be explained by the reduced
amount of OXA, and consequently by its decrease serum peak
concentration after each administration. Overall, 44% of
patients treated with OXAFAFUld and 53% treated with IRI-
FAFU suffered from at least one episode of grade >_3 toxicity
(except for alopecia). Early deaths (within 60 days from initial
therapy) were 4% in both the IRIFAFU and OXAFAFU
groups. Five patients died because of severe adverse events
possibly or probably related to the received treatment: three
patients (two in the IRIFAFU group and one in the OXAFA-
FUhd group) died as a consequence of severe diarrhoea; one
patient died of myocardial infarction after the first course of
IRIFAFU, and another patient had a gastric haemorrhage after
the first course of OXAFAFUld.
FFS and OS
After a median follow-up of 24 months (range 10–36), 252
(91%) patients had an induction failure, and 150 (54%)
patients died. According to treatment, median FFS was 5.8
months (95% CI 4.4–7.2) for patients treated with IRIFAFU,
6 months (95% CI 4.4–7.6) for patients treated with OXAFA-
FUhd and 7.6 months (95% CI 5.9–9.3) for patients treated
with OXAFAFUld. Median OS was 15.6 months (95% CI
13.5–17.9) for IRIFAFU and 18.9 months (95% CI 15.3–
22.5) for OXAFAFU. In detail, median OS was 17.6 months
(95% CI 13.1 to 22.1) for patients treated with OXAFAFUhd,
while it exceeded 23 months for patients treated with OXA-
FAFUld.
PS was the baseline clinical feature mostly affecting the
outcome of patients. Indeed, FFS was 8.3 months and OS 20.5
months, for patients with PS 0, as opposed to 3.4 months and
11.1 months, respectively, for patients with PS >_1. The differ-
ence of FFS for patients treated with IRI and those treated
with OXA was statistically significant (P = 0.046) when
adjusted for PS (Figure 1). Comparison of OS between IRI-
and OXA-treated patients, which was of borderline signifi-
cance (P = 0.058), reached a significant level (P = 0.032) when
adjusted for PS. It is noteworthy that OS curves of the two
groups of patients progressively diverged after the first year of
follow-up: indeed, survival probability was 60% versus 65%
at 12 months, 42% versus 52% at 18 months, and 23% versus
39% at 24 months, respectively (Figure 2). Moreover, we
noted that OS of patients sequentially treated with all three
active drugs, i.e. 5-FU, IRI and OXA, was significantly longer
in comparison with that of patients not receiving all three
drugs (median 16.6 versus 13 months, respectively)
(P = 0.009).
Discussion
First of all, we wish to remark that the activity of the IRI-
FAFU regimen in this and in our previous study [11] was
comparable. This observation supports the reproducible effi-
cacy of IRIFAFU in metastatic colorectal cancer. Moreover,
activity and toxicity of IRIFAFU appeared quite similar to
those reported with IFL [9].
With these premises in mind, we believe that the present
trial provided evidence that OXAFAFU is more active than
IRIFAFU. Indeed, the greater RR was obtained using stringent
criteria (i.e. including only confirmed responses). Moreover,
this greater activity was independent of PS and CEA baseline
value, which were the only pretreatment variables affecting
RR in the multivariate analysis, and it was obtained despite
the dose reduction implemented after the interim analysis on
toxicity. Therefore, RR of OXAFAFU was not related to the
dosage, provided that a similar number of cycles, duration of
treatment and DI were administered in the two groups of
patients treated with this regimen.
The higher RR was obtained at the price of similar occur-
rence of haematological toxicity (with amended dosages), and
lower non-haematological toxicity in comparison with IRI-
FAFU. The better tolerability was also confirmed by a longer
FFS time. Since FFS is also affected by factors other than PD,
we believe it provided a clinically important measurement of
the treatment on study in comparison with the reference
Figure 1. Failure-free survival curves according to treatment (black line,
OXAFAFU; grey line, IRIFAFU). OXAFAFU, oxaliplatin plus high-dose
folinic acid and 5-fluorouracil i.v. bolus; IRIFAFU, irinotecan plus high-
dose folinic acid and 5-fluorouracil i.v. bolus.
Figure 2. Overall survival curves according to treatment (black line,
OXAFAFU; grey line, IRIFAFU). OXAFAFU, oxaliplatin plus high-dose
folinic acid and 5-fluorouracil i.v. bolus; IRIFAFU, irinotecan plus high-
dose folinic acid and 5-fluorouracil i.v. bolus.
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regimen. Patients compliance was favoured by our policy of
delivering a maximum of 12 cycles, so that chronic toxicities,
namely OXA-induced peripheral neuropathy, rarely occurred.
This is in contrast with other trials, in which neuropathy with
functional impairment was reported in higher proportions of
patients [20, 21, 33, 34].
Recently, two trials randomly compared OXA and IRI
associated with FA/5-FU in advanced colorectal cancer
patients (Table 5). In the GERCOR study, patients were trea-
ted biweekly with l-FA 200 mg/m2 infusion, plus 5-FU
400 mg/m2 bolus and 2400–3000 mg/m2 infusional over 46 h,
preceded by either OXA 100 mg/m2 (FOLFOX6) or IRI
180 mg/m2 (FOLFIRI) [33]. After PD, patients received the
alternative regimen in a cross-over design. In this study, no
differences in RR, PFS or OS were observed. The conclusions
were that the two regimens used sequentially provided an out-
standing long survival, and that any efforts should be made in
the future for increasing the proportion of patients who will
receive both treatments.
Goldberg et al. [34] reported comparative results of three
regimens: IFL, FOLFOX4, and IROX (a combination of IRI
and OXA). In this study, all the efficacy parameters (RR, 45%
versus 31%; PFS, 8.7 versus 6.9 months; OS, 19.5 versus 15
months), as well as the acute toxicity profile, favoured the
FOLFOX4 in comparison with the IFL. These investigators
concluded that FOLFOX4 should be considered as first-line
standard of care for metastatic colorectal cancer [34]. How-
ever, because of different doses and schedules of 5-FU, these
results could not isolate, at least in terms of activity, the rela-
tive independent contribution of OXA versus IRI, and of
infused versus bolus 5-FU. Furthermore, as recently pointed
out [35], this trial had the drawback of an imbalanced
proportion of patients receiving second-line treatments.
Therefore, our study was the first one directly comparing
OXA and IRI, both associated with FA/5-FU i.v. bolus.
The results of this trial demonstrated that OXAFAFU was
more active than IRIFAFU. Moreover, patients treated with
OXAFAFU had a significantly longer FFS and OS. At this
point, it is important to remember that our trial was not pow-
ered to reach a level of significance with an actual 3-month
difference in median OS. However, it has recently been
stressed that the lack of a statistically significant survival pro-
longation in trials assessing combination regimens in meta-
static colorectal cancer patients should not be interpreted as an
evidence of no survival benefit at all [36].
Our findings were obtained despite the fact that similar pro-
portions of patients in both arms were given second- and
third-line treatment, and received sequentially all three active
drugs. It may be extrapolated from the GERCOR trial that
FOLFOX6 was more active after failure of FOLFIRI regimen
than vice versa (RR 15% versus 4%, and PFS 4.2 versus 2.5
months, respectively). If we apply this observation to our
patients, we could argue that an OXA-based regimen in
second-line, although more active, did not compensate for a
less active IRI-based treatment in first-line. In fact, we
observed that median OS for patients sequentially receiving
all three cytotoxic agents differed according to front-line treat-
ment: it was 18.6 months for patients in OXAFAFU arm, and
15.9 months for patients in IRIFAFU arm. For these reasons,
we believe that OXAFAFU should be used first in the treat-
ment of metastatic colorectal cancer patients. Moreover, it
should be taken into account that not all patients will receive
second-line treatment. In our experience, the proportion of
these patients is progressively increasing, from  40% of our
previous study to >50% in the present one. However, many
patients still do not receive salvage treatment for several
reasons. For these patients, survival expectancy is affected
only by the front-line treatment. Therefore, it is crucial for
them to receive the most tolerable and effective regimen,
Table 5. Efficacy and toxicity of 5-FU and FA with either oxaliplatin or irinotecan in advanced colorectal carcinoma (randomised trials)
Study, author Arm Patients ACT
(%)
PS 0–1
(%)
Liver+
(%)
RR
(%)
PFS
(months)
MST
(months)
60-day
mortality (%)
Neutropenia
(%)
Diarrhoea
(%)
Neuropathy
(%)
GERCOR,
Tournigand [33]
FOLFOX6 111 21 94 80 54 8.0 20.6 3 44 11 34
P= 0.003
FOLFIRI 109 17 83 87 56 8.5 21.5 4 24 14 0
N9741,
Goldberg [34]
FOLFOX4 267 16 93 NA 45 8.7 19.5 2.6 50 12 18
P= 0.002 P= 0.0014 P= 0.0001 P= 0.04 P= 0.001 P= 0.001
IFL 264 15 93 NA 31 6.9 15.0 4.5 40 28 3
SICOG 0103,
present study
OXAFAFU 140 24 97 78 44 8.2 18.9 4 29 12 3
P= 0.029 P= 0.032 P= 0.005
IRIFAFU 136 25 97 73 31 7.5 15.6 4 31 28 1
ACT, adjuvant chemotherapy; PS, performance status; RR, response rate; PFS, progression-free survival; MST, median survival time; FOLFOX, biweekly
infusional plus bolus FA/5-FU + oxaliplatin; FOLFIRI, biweekly infusional plus bolus FA/5-FU + irinotecan; IFL, weekly bolus FA/5-FU + irinotecan;
OXAFAFU, biweekly bolus FA/5-FU + oxaliplatin; IRIFAFU, biweekly bolus FA/5-FU + irinotecan; 5-FU, 5-fluorouracil; FA, folinic acid.
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because a significant correlation between RR and survival has
already been established for these patients [37].
In conclusion, the OXAFAFU regimen showed activity and
toxicity comparable with those reported with the FOLFOX4.
In our opinion, the OXAFAFU is preferable because it does
not require central venous catheter and infusional devices,
being more comfortable for outpatient treatment and less
costly. For these reasons, the OXAFAFU regimen is from
now on the reference regimen for SICOG investigators, to be
challenged in future trials.
Acknowledgements
We acknowledge the contribution of Dr Anna Crispo, and
Dr Maurizio Montella for the statistical analysis. We also
wish to thank Dr Marina Lincenziato for her excellent data
management, and Ms Liliana Gallifuoco for her invaluable
secretarial assistance. This work was supported by Aventis
Pharma, Milan and Sanofi Synthelabo, Milan, Italy.
Other SICOG investigators (and Institutions) taking part in
this trial were: Rossana Casaretti, Antonio Avallone (National
Tumour Institute, Naples); Maria Teresa Ionta (University
Medical School, Cagliari); Antonio Gambardella (Second Uni-
versity Medical School, Naples); Giuseppe De Cataldis (Da
Procida Hospital, Salerno); Anna Russo (University Medical
School, Palermo); Salvatore Del Prete (City Hospital, Fratta-
maggiore); Annunziato Iannelli (City Hospital, Siderno);
Maria di Grazia (City Hospital, Caserta); Teresa Bellelli
(Clinic Malzoni, Agropoli); Enrico Barbato (City Hospital
Aversa); Maddalena Bianco (City Hospital, Castellammare);
Liberato Di Lullo (City Hospital, Isernia); Ettore Greco (City
Hospital, Lametia); Filomena Del Gaizo (City Hospital,
Avellino); and Sergio Catanzani (City Hospital, Terni, Italy).
References
1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of
fluorouracil by leucovorin in patients with advanced colorectal cancer:
evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
2. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of
randomized trials testing the biochemical modulation of fluorouracil
by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;
12: 960–969.
3. Abad A, Garcia P, Gravalos C et al. Sequential methotrexate, 5-fluor-
ouracil (5FU), and high dose leucovorin versus 5-FU and high dose
leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer
1995; 75: 1238–1244.
4. Glimelius B. Biochemical modulation of 5-fluorouracil: A randomized
comparison of sequential methotrexate, 5-fluorouracil and leucovorin
versus sequential 5-fluorouracil and leucovorin in patients with advan-
ced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235–250.
5. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leu-
covorin in patients with advanced colorectal cancer: An updated
meta-analysis. J Clin Oncol 2004; 22: 3766–3775.
6. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing
monthly low-dose leucovorin and fluorouracil bolus with bimonthly
high-dose leucovorin and fluorouracil bolus plus continuous infusion
for advanced colorectal cancer: A French Intergroup study. J Clin
Oncol 1997; 15: 808–815.
7. Ko¨hne C-H, Wils J, Lorenz M et al. Randomized phase III study of
high-dose fluorouracil given as a weekly 24-hour infusion with or
without leucovorin versus bolus fluorouracil plus leucovorin in
advanced colorectal cancer. European Organization of Research and
Treatment of Cancer Gastrointestinal Group study 40952. J Clin
Oncol 2003; 21: 3721–3728.
8. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irino-
tecan versus fluorouracil by continuous infusion after fluorouracil fail-
ure in patients with metastatic colorectal cancer. Lancet 1998; 352:
1407–1412.
9. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leu-
covorin for metastatic colorectal cancer. N Engl J Med 2000; 343:
905–914.
10. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined
with fluorouracil compared with fluorouracil alone as first-line treat-
ment for metastatic colorectal cancer: A multicentre randomised trial.
Lancet 2000; 355: 1041–1047.
11. Comella P, Crucitta E, De Vita F et al. Addition of either irinotecan
or methotrexate to bolus fluorouracil and high-dose leucovorin every
two weeks in advanced colorectal carcinoma: A randomized study of
the Southern Italy Cooperative Oncology Group. Ann Oncol 2002;
13: 866–873.
12. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin:
A review of preclinical and clinical studies. Ann Oncol 1998; 9:
1053–1071.
13. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin
as first-line chemotherapy in metastatic colorectal cancer patients.
J Clin Oncol 1998; 16: 2739–2744.
14. Dı´az-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent
in previously untreated colorectal carcinoma patients: A phase II mul-
ticentric study. Ann Oncol 1998; 9: 105–108.
15. Machover D, Dı´az-Rubio E, De Gramont A et al. Two consecu-
tive phase II study of oxaliplatin (L-OHP) for the treatment of
patients with advanced colorectal carcinoma who were resistant to
previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:
95–98.
16. Fischel J-L, Etienne M-C, Formento P, Milano G. Search for the opti-
mal schedule for the oxaliplatin/5-fluorouracil association modulated
or not by folinic acid: Preclinical data. Clin Cancer Res 1998; 4:
2529–2535.
17. Brienza S, Besmaine MA, Soulie P et al. Oxaliplatin added to 5-fluor-
ouracil-based therapy (5-FU +/ FA) in the treatment of 5-FU pre-
treated patients with advanced colorectal cancer (ACRC): Results
from the European compassionate use program. Ann Oncol 1999; 10:
1311–1316.
18. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxalipla-
tin and fluorouracil–leucovorin compared with either therapy alone in
patients progressive colorectal cancer after irinotecan and fluoroura-
cil–leucovorin: Interim results of a phase III trials. J Clin Oncol
2003; 21: 2059–2069.
19. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter ran-
domized trial of oxaliplatin added to chronomodulated fluorouracil–
leucovorin as first-line treatment of metastatic colorectal cancer. J Clin
Oncol 2000; 18: 136–147.
20. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluoroura-
cil with or without oxaliplatin as first-line treatment in advanced col-
orectal cancer. J Clin Oncol 2000; 18: 2938–2947.
21. Ravaioli A, Marangolo M, Pasquini E et al. Bolus fluorouracil and
leucovorin with oxaliplatin as first-line treatment in metastatic color-
ectal cancer. J Clin Oncol 2002; 20: 2545–2550.
22. Zori Comba A, Blajman C, Richardet E et al. A randomized phase
II study of oxaliplatin alone versus oxaliplatin combined with
885
5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously
untreated metastatic colorectal cancer patients. Eur J Cancer 2001;
37: 1006–1013.
23. Hochster HS, Chachoua A, Speyer J et al. Oxaliplatin with weekly
bolus fluorouracil and low-dose leucovorin as first line therapy for
patients with advanced colorectal cancer. J Clin Oncol 2003; 21:
2703–2707.
24. Sørbye H, Glimelius B, Berglund A et al. Multicenter phase II study
of Nordic fluorouracil and folinic acid bolus schedule combined with
oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin
Oncol 2004; 22: 31–38.
25. Comella P. Randomized trial comparing the addition of either oxali-
platin or irinotecan to high-dose folinic acid and 5-fluorouracil i.v.
bolus every two weeks in metastatic colorectal carcinoma: A Southern
Italy Cooperative Oncology Group study (SICOG 0103). Clin Color-
ectal Cancer 2003; 3: 186–189.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results
of cancer treatment. Cancer 1981; 47: 207–214.
27. Le´vi F, Misset JL, Brienza S et al. A chronopharmacologic phase II
clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using
ambulatory multichannel programmable pump. High antitumor effec-
tiveness against metastatic colorectal cancer. Cancer 1992; 69:
893–900.
28. Simon R. Design and conduct of clinical trials. In De Vita VT Jr,
Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of
Oncology, 4th edition. Philadelphia, PA: JB Lippincott Co. 1993;
418–440.
29. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing
among experimental treatments and a control in clinical trials.
Biometrics 1989; 45: 537–547.
30. Cochran WG. Some methods for strengthening the common
chi-square test. Biometrics 1954; 10: 417–451.
31. Kaplan ES, Meier P. Non parametric estimation for incomplete
observations. J Am Stat Assoc 1958; 53: 557–580.
32. Mantel N. Evaluation of survival data and two new ranks of order
statistics arising in its considerations. Cancer Chemother Rep 1966;
50: 163–170.
33. Tournigand C, Andre´ T, Achille E et al. FOLFIRI followed
by FOLFOX6 or the reverse sequence in advanced colorectal cancer:
A randomized GERCOR study. J Clin Oncol 2004; 22: 229–237.
34. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled
trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combi-
nations in patients with previously untreated metastatic colorectal can-
cer. J Clin Oncol 2004; 22: 23–30.
35. Punt CJA. New options and old dilemmas in the treatment of patients
with advanced colorectal cancer. Ann Oncol 2004; 15: 1453–1459.
36. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary
end point in advanced colorectal cancer studies? A critical assessment
based on four clinical trials comparing fluorouracil plus leucovorin
plus the same treatment combined with either oxaliplatin or CPT-11.
Ann Oncol 2004; 15: 545–549.
37. Buyse M, Thirion P, Carlson RW et al. Relation between tumor
response to first-line chemotherapy and survival in advanced colorecal
cancer: A meta-analysis. Lancet 2000; 356: 373–378.
886
